Acorda Therapeutics ACOR today announced that the
Company has completed the acquisition of Neuronex, Inc., a privately
held company developing a nasal spray formulation of diazepam. Under the
terms of the agreement, Acorda paid $6.8 million to Neuronex to complete
the acquisition.
“Diazepam Nasal Spray is an important addition to our pipeline and
aligns with our core strategy to develop and commercialize products that
offer unique benefits to people with neurological diseases,” said Ron
Cohen, M.D., Acorda's President and CEO. “This product leverages our
existing sales, marketing and medical organizations, which have proved
highly successful in bringing novel neurological therapies to market.”
Diazepam Nasal Spray is
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in